Core Insights - The company reported a slight increase in revenue for 2024, with total revenue, net profit attributable to shareholders, and net profit excluding non-recurring items reaching 2.554 billion, 787 million, and 745 million respectively, representing year-on-year growth of 2.62%, 9.79%, and 2.99% [1] - The company experienced a significant decline in Q4 2024 revenue and net profit compared to the previous quarter, with revenue down 27.4% year-on-year [1] - In Q1 2025, the company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 577 million, 193 million, and 190 million respectively, with year-on-year changes of -8.58%, +14.18%, and +15.17% [1] Revenue Breakdown - The company's non-lithium basic warehouse business showed strong growth, with total revenue excluding the lithium extraction project from salt lakes reaching 2.455 billion, a year-on-year increase of 24.71% [2] - The salt lake lithium extraction project generated only 99 million in revenue, down 81% year-on-year, impacting overall revenue growth [2] - Revenue from various application areas in adsorption materials included: 256 million from metal resources (+30%), 568 million from life sciences (+28%), 688 million from water treatment and ultrapure water (+34%), 181 million from energy conservation and environmental protection (-2%), 56 million from food processing (+28%), and 200 million from chemicals and catalysis (+42%) [2] Profitability and Margins - The company achieved a gross margin of 49.47% in 2024, an increase of 0.8 percentage points year-on-year, benefiting from a higher proportion of mid-to-high-end adsorption materials and a decrease in the proportion of lower-margin system device revenue [2] - In Q1 2025, the gross margin improved to 50.79%, up 5.37 percentage points year-on-year, with continued strong growth in the life sciences, metal resources, and water treatment sectors [2] International Expansion - The company saw a significant increase in overseas revenue, which reached 655 million in 2024, a year-on-year growth of 45.1%, accounting for 25.65% of total revenue [3] - The company established a wholly-owned subsidiary in the United States and set up warehousing units in North America and Europe to facilitate localized business development [3] Future Projections - Revenue projections for 2025-2027 are estimated at 3.085 billion, 3.824 billion, and 4.679 billion respectively, with year-on-year growth rates of 20.78%, 23.98%, and 22.34% [3] - Net profit attributable to shareholders is expected to reach 959 million, 1.204 billion, and 1.548 billion for the same period, with growth rates of 21.85%, 25.55%, and 28.53% respectively [3] - The current stock price corresponds to a price-to-earnings ratio of 23.34, 18.59, and 14.47 for 2025-2027, reflecting the company's strong growth potential as a leading platform for adsorption materials [3]

Core Viewpoint - The company reported a stable revenue growth in 2024, with a total revenue of 2.554 billion yuan, reflecting a year-on-year increase of 2.62%, while net profit attributable to shareholders reached 787 million yuan, up 9.79% year-on-year [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 2.554 billion yuan, with a net profit of 787 million yuan and a non-recurring net profit of 745 million yuan, showing year-on-year increases of 9.79% and 2.99% respectively [1] - The profit distribution plan for 2024 proposes a dividend of 6.00 yuan per 10 shares (including tax) [1] - For Q1 2025, the company reported a revenue of 577 million yuan, down 8.58% year-on-year and 12.91% quarter-on-quarter, while net profit attributable to shareholders was 193 million yuan, up 14.18% year-on-year [1] Group 2: Business Segments - The basic warehouse business showed robust growth, with a revenue of 2.45 billion yuan excluding the lithium extraction project, marking a 24.7% year-on-year increase and accounting for 96.1% of total revenue [2] - The ion exchange adsorption resin segment generated 1.99 billion yuan in revenue, a 27.6% increase year-on-year, with a gross margin of 52.85%, reflecting a 1.72 percentage point increase [2] - Revenue from water treatment, life sciences, metal resources, and chemical & catalysis segments grew by 34%, 28%, 30%, and 42% respectively [2] Group 3: Project and Market Dynamics - The revenue from the lithium extraction project was 100 million yuan, accounting for 3.9% of total revenue, which represents an 81.0% year-on-year decline due to cyclical downturns in the lithium resource industry [3] - The company has received 195 million yuan from a contract signed in March 2022 for the supply of adsorption equipment, indicating a discrepancy with the expected progress [3] Group 4: Research and Development - The company invested 146 million yuan in R&D in FY 2024, representing 5.72% of revenue, and 33 million yuan in Q1 2025, maintaining a similar ratio of 5.71% [4] - The ongoing antitrust investigation into DuPont may accelerate the company's penetration into high-end product markets [4] - In the life sciences sector, the company completed the scale-up validation of a new generation ProteinA affinity filler, receiving positive feedback from multiple clients [4] Group 5: Investment Outlook - The company is expected to achieve net profits of 1.012 billion yuan, 1.262 billion yuan, and 1.526 billion yuan for 2025-2027, with corresponding PE ratios of 22x, 18x, and 15x [4] - A target price of 59.70 yuan is set for 2025 based on a 30x PE valuation, maintaining a strong buy rating [4]

Group 1 - The company reported Q1 2025 revenue of 5.44 billion yuan, a year-on-year increase of 20.9% and a quarter-on-quarter decrease of 6.66% [1] - The net profit attributable to the parent company reached 1.88 billion yuan, a year-on-year increase of 116.2% and a slight quarter-on-quarter increase, achieving a new record high [1] - The significant growth in performance is primarily attributed to the rise in prices of Vitamin E (VE) and methionine, with expectations for sustained high prices due to improved supply and demand dynamics [1][3] Group 2 - The average prices for VA/VE/VC/methionine in Q1 were 112.3/136.4/28.3/20.9 yuan/kg, representing year-on-year increases of 37.4%/109.9%/15.6%/-4.2% [2] - The company maintained a stable operation with a period expense ratio of 7%, which has been decreasing both year-on-year and quarter-on-quarter [2] - The gross profit margin was 46.7%, an increase of 11.7 percentage points year-on-year, while the net profit margin was 34.7%, an increase of 13.3 percentage points year-on-year [2] Group 3 - The supply-demand improvement in the methionine and VE markets is expected to support high price levels, with DSM planning to exit the vitamin market and leading methionine producers reducing production [3] - Recent price increases for methionine and VE are anticipated to positively impact the company's performance, with each 1 yuan/kg increase in price expected to add approximately 280 million yuan and 45 million yuan to profits, respectively [3] - The new materials business is experiencing rapid growth, with investments in various projects expected to accelerate future growth [3] Group 4 - The company forecasts net profits attributable to the parent company of 7.87 billion, 9.38 billion, and 9.76 billion yuan for 2025-2027, with corresponding EPS of 2.56, 3.05, and 3.18 yuan [4] - The current price corresponds to a PE ratio of 8.7, 7.3, and 7.0 for the respective years, maintaining a "buy" rating [4]

Financial Performance - The company reported a basic earnings per share of 0.2231 yuan for 2024, a significant increase of 539.26% compared to 0.0349 yuan in 2023 [1] - Net profit for 2024 reached 2.57 billion yuan, up 542.5% from 0.4 billion yuan in the previous year [1] - Operating revenue decreased to 77.16 billion yuan, down 35.13% from 118.95 billion yuan in 2023 [1] - Return on equity improved to 2.46% from 0.38% in the previous year, marking a 547.37% increase [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 15,485.55 million shares, accounting for 14.64% of the circulating shares, with a decrease of 849.45 million shares compared to the previous period [1] - Notable shareholders include Zhang Ting with 4,190.00 million shares (3.96%) and Zheng Rong with 2,937.98 million shares (2.78%), both remaining unchanged [2] - New entrants among the top shareholders include China Life Insurance with 1,504.63 million shares (1.42%) and several funds, while South China CSI 500 ETF exited the top ten [2] Dividend Distribution - The company announced a dividend distribution of 0.4 yuan per share (tax included) [3]

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1799 | -0.4915 | 63.4 | -0.5800 | | 每股净资产（元） | 0.16 | 0.35 | -54.29 | 0.83 | | 每股公积金(元) | 2.54 | 2.55 | -0.39 | 2.54 | | 每股未分配利润(元) | -3.45 | -3.27 | -5.5 | -2.78 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.31 | 5.74 | -7.49 | 5.85 | | 净利润(亿元) | -0.59 | -1.6 | 63.13 | -1.88 | | 净资产收益率(%) | -70.47 | -84.02 | 16.13 | -52.22 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5944.84万股，累计占流通股比 ...

| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.3539 | -0.0890 | -297.64 | -0.1798 | | 每股净资产（元） | 3.26 | 3.25 | 0.31 | 3.35 | | 每股公积金(元) | 1.46 | 0.98 | 48.98 | 0.98 | | 每股未分配利润(元) | 0.80 | 1.19 | -32.77 | 1.28 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 9.24 | 7.97 | 15.93 | 8.91 | | 净利润(亿元) | -1.82 | -0.46 | -295.65 | -0.93 | | 净资产收益率(%) | -10.32 | -2.42 | -326.45 | -4.69 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 三、分红送配方案情况 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 ...

三、分红送配方案情况 不分配不转增 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 4468.19万股，累计占流通股比： 58.17%，较上期变化： -46.26万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 桐乡市顺昌投资有限公司 | 2983.55 | 38.84 | 不变 | | 桐乡中祥化纤有限公司 | 457.12 | 5.95 | 不变 | | 杨绍校 | 370.77 | 4.83 | 196.48 | | HOST VANTAGE ASIA LIMITED | 215.30 | 2.80 | 不变 | | 薛明 | 113.52 | 1.48 | 2.24 | | 邹杰 | 76.80 | 1.00 | 2.03 | | 吕强 | 75.00 | 0.98 | -58.17 | | 周晔 | 63.99 | 0.83 | 不变 | | 袁力 | 56.57 | 0.74 | 新进 | | 李峰 | 55.57 | 0.72 | 新进 | | 较上个报告期退出前十大股东有 | | | ...

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 前十大流通股东累计持有： 34251.77万股，累计占流通股比： 50.61%，较上期变化： -875.37万股。 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2500 | -0.3400 | 173.53 | -0.3000 | | 每股净资产（元） | 5.79 | 5.55 | 4.32 | 5.96 | | 每股公积金(元) | 1.6 | 1.65 | -3.03 | 1.64 | | 每股未分配利润(元) | 2.65 | 2.39 | 10.88 | 2.85 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 16.38 | 16.91 | -3.13 | 19.32 | | 净利润(亿元) | 1.7 | -2.41 | 170.54 | -2.1 | | 净资产收益率(%) | 4.39 | -5 ...

Core Viewpoint - The company is optimistic about the future of the radiation curing industry, driven by technological advancements, policy support, and market expansion opportunities [3][4]. Industry Outlook - Technological advancements in radiation curing, particularly in light curing technology, are expected to drive industry innovation, offering efficiency, cost-effectiveness, and environmental benefits [3]. - The market share of light curing technology in inks and coatings remains low, indicating significant future growth potential [3]. - National policies are supporting the upgrade of the industry by including high-end light initiators and new light curing materials in relevant guidance directories [3]. - The application of light initiators is expanding from traditional printing to high-tech industries such as optoelectronics, information and communication, and 3D printing [3]. Market Competition - The radiation curing industry is experiencing increased production capacity, leading to fierce competition and a supply-demand imbalance, particularly in 2024 [4]. - Major competitors in the light initiator sector include the company, IGM, Jiu Ri New Materials, Qiangli New Materials, and Gurin Technology, with expectations for increased industry concentration [4]. - The company maintains a stable market share due to its comprehensive product series and advanced production technology, despite short-term competition in the dye industry [4]. Company Strategies - The company is optimizing its organizational structure and governance to enhance operational efficiency and integrate its resources effectively [5]. - It is implementing an incentive mechanism linking employee income to production base revenue and profits, aiming to improve profitability [5]. - The company is adjusting its production lines to focus on high-demand products and increasing R&D investment in new products and technologies [5][6]. - It plans to enhance brand recognition and expand into overseas markets to increase its international presence [7]. Financial Performance - In Q1 2025, the company reported a main revenue of 232 million yuan, a year-on-year increase of 74.6%, and a net profit attributable to shareholders of 10.05 million yuan, up 174.81% [9]. - The company's gross profit margin stands at 17.96%, with a debt ratio of 46.42% [9].

同益股份（300538）公告，2024年营业收入30.75亿元，同比下降5.57%。归属于上市公司股东的净亏损 9551.91万元，去年同期净利润2604.55万元，由盈转亏。基本每股收益-0.53元/股。公司计划不派发现金 红利，不送红股，不以公积金转增股本。 ...